Pharmacokinetics of maraviroc, raltegravir, darunavir, and etravirine in the Semen of HIV-infected men

Journal of Acquired Immune Deficiency Syndromes

Volumn 62, Issue 2, 2013, Pages

  Antoniou, Tony ^a,b   Hasan, Sumaira ^c   Loutfy, Mona R ^d,e,f   Kovacs, Colin ^e,g   Brunetta, Jason ^g   Smith, Graham ^g   Halpenny, Roberta ^g   La Porte, Charles ^c  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f WOMEN S COLLEGE HOSPITAL   (Canada)

^g MAPLE LEAF MEDICAL CLINIC   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DARUNAVIR; ETRAVIRINE; MARAVIROC; RALTEGRAVIR;

ADULT; AREA UNDER THE CURVE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG PROTEIN BINDING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; SEMEN ANALYSIS; SEMINAL PLASMA; TIME TO MAXIMUM PLASMA CONCENTRATION; VIRUS LOAD;

ANTI-HIV AGENTS; AREA UNDER CURVE; CYCLOHEXANES; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRIDAZINES; PYRROLIDINONES; SEMEN; SULFONAMIDES; TRIAZOLES;

EID: 84872848368     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31827a0d71     Document Type: Letter

References (16)

1. Else LJ, Taylor S, Back DJ, et al. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary site: the male and female genital tract. Antivir Ther. 2011;16:1149-1167.
2. Brown KC, Patterson KB, Malone SA, et al. Single and multiple dose pharmacokinetics of maraviroc in saliva, semen and rectal tissue of healthy HIV-negative men. J Infect Dis. 2011; 203:1484-1490.
3. Brown KC, Patterson KB, Jennings SH, et al. Single and multiple dose pharmacokinetics of darunavir plus ritonavir and etravirine in semen and rectal tissue of HIV-negative men. J Acquir Immune Defic Syndr. 2012;61:138-144.
4. DeJesus E, Lalezari JP, Osiyemi OO, et al. Pharmacokinetics of once-daily etravirine without and without once-daily darunavir/ritonavir in antiretroviral naive HIV type-1-infected adults. Antivir Ther. 2010;15:711-720.
5. De Meyer S, Azijn H, Surleraux D, et al. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant virus, including a broad range of clinical isolates. Antimicrob Agents Chemother. 2005;49:2314-2321. (Pubitemid 40734460)
6. European Medicines Agency. Celsentri: EPAR product information. Available at: http://www.emea.europa.eu/docs/en-GB/document-library/EPAR-Product- Information/human/000811/WC500022190.pdf. Accessed July 27, 2012.
7. Hughes CA, Robinson L, Tseng A, et al. New antiretroviral drugs: a review of the efficacy, safety, pharmacokinetics, and resistance profile of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir. Expert Opin Pharmacother. 2009;10:2445-2466.
8. Kromdijk W, Huitema AD, Mulder JW. Treatment of HIV infection with the CCR5 antagonist maraviroc. Expert Opin Pharmacother. 2010;11:1215-1223.
9. Temesgen Z, Siraj DS. Raltegravir: first in class HIV integrase inhibitor. Ther Clin Risk Manag. 2008;4:493-500. (Pubitemid 351712008)
10. Cao YJ, Hendrix CW. Male genital tract pharmacology: developments in quantitative methods to better understand a complex peripheral compartment. Clin Pharmacol Ther. 2008;83:401-412. (Pubitemid 351272639)
11. IwamotoM,Wenning LA, Petry AS, et al. Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects. Clin Pharmacol Ther. 2008;83:293-299.
12. Avery LB, Rakshi RP, Cao YJ, et al. The male genital tract in not a pharmacological sanctuary from efavirenz. Clin Pharmacol Ther. 2011;90:151-156.
13. Barau C, Delaugerre C, Braun J, et al. High concentration of raltegravir in semen of HIVinfected men: results from a substudy of the EASIER-ANRS 138 trial. Antimicrob Agents Chemother. 2010;54:937-939.
14. Tiraboschi JM, Niubo J, Curto J, et al. Maraviroc concentrations in seminal plasma in HIV-infected patients. J Acquir Immune Defic Syndr. 2010;55:e35-e36.
15. Calcagno A, Bonora S, D'Avolio A, et al. Raltegravir penetration in seminal plasma of healthy volunteers. Antimicrob Agents Chemother. 2010;54:2744-2745.
16. Taylor S, Jayasuirya AN, Berry A, et al. Darunavir concentrations exceed the proteincorrected EC50 for wild-type HIV in the semen of HIV-1 infected men. AIDS. 2010; 24:2583-2587.